NCT05745623RecruitingPhase 1/2
Study of ICP-723 in Patients With Advanced Solid Tumors or Primary Central Nervous System Tumors
A Multi-center, Non-Randomized, Open-Label Phase 2 Basket Clinical Trial to Evaluate ICP-723 in Patients With Advanced Solid Tumors or Primary Central Nervous System Tumors
Source: ClinicalTrials.gov · Last updated 11 Sept 2025 · Not updated for over 12 months - ask the site whether it is still open
Brief summary (registry, in English)
A Multi-center, Non-Randomized, Open-Label Phase 2 Basket Clinical Trial to Evaluate ICP-723 in Patients with Advanced Solid Tumors or Primary Central Nervous System Tumors
- Status (registry)
- Recruiting
- Phase (registry)
- Phase 1/2
- Study type
- Interventional
- Enrollment
- 70 (estimated)
- First submitted
- 16 Feb 2023
- Start date
- 27 Dec 2022
- Primary completion date
- 25 Dec 2027
- Lead sponsor
- Beijing InnoCare Pharma Tech Co., Ltd.
- Diseases
- Childhood cancers
- NCT number
- NCT05745623
What you commit to
- Study type: Interventional · Phase 1/2
- Planned participants: 70
- From 27 Dec 2022 to the primary completion date, 25 Dec 2027
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- Grade 1 or higher toxicities attributed to any previous treatment not yet recovered.
Other illness
- Other conditions considered unsuitable for participation in this trial at the discretion of the investigator
Lab values
- Patients with abnormal QTc interval at screening, or other clinically significant abnormalities in electrocardiographic examination at the discretion of the investigator.
Other
- Patients with unstable primary central nervous system (CNS) tumors or CNS metastasis.
- Patient with recent anti-tumor and other treatment as stated in the protocol.
Who the study is looking for
- Eastern Cooperative Oncology Group (ECOG) performance status of 0-1;
- Patients with advanced solid tumors or primary central nervous system (CNS) tumors harboring NTRK gene fusions as detected by the designated central laboratory, who received no previous NTRK inhibitor treatment;
- At least one measurable lesion as per RECIST1.1 criteria, or for primary CNS tumors, at least one measurable lesion as per RANO or INRC criteria.
- Organ functions meet the clinical criteria
Age in the registry: 2 years to - · Sex: All · Does not accept healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Sun Yat-sen University Cancer Center Coordinator of this site? Confirm its status | Guangzhou | China | Recruiting |
This page is information, not medical advice. Discuss any trial with your doctor.